Publications by authors named "H J Streicher"
Background: Anti-programmed death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies.
Objectives: This study presents the first results of ipilimumab-nivolumab in invasive mucinous or non-mucinous lepidic adenocarcinoma (invasive mucinous adenocarcinoma (IMA) or invasive non-mucinous lepidic adenocarcinomas (INLA), respectively) of the lung.
Design: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) is a prospective, open-label, multicenter (1016 US sites), multi-cohort phase II trial of ipilimumab (1 mg/kg intravenously (IV) every 6 weeks) plus nivolumab (240 mg IV every 2 weeks).
Article Synopsis
- This study investigates the relationship between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and survival outcomes in patients with rare cancers, utilizing data from a federally-funded basket trial involving 684 participants.
- The research indicates that grade 1-2 treatment-related irAEs are linked to longer overall survival, while grade 3-4 irAEs are associated with shorter survival, with similar but weaker effects on progression-free survival.
- Specific types of grade 1-2 dermatologic toxicity were particularly beneficial for overall survival, highlighting the predictive value of the severity of irAEs in treatment outcomes for rare tumors.
Article Synopsis
- The SWOG S1609 DART trial investigated the effectiveness of dual therapy with ipilimumab and nivolumab in patients with vulvar cancers, showing initial promising results.
- In this phase II clinical trial involving 16 patients, the objective response rate was 18.8%, with some patients exhibiting durable responses and stable disease.
- Adverse effects were common, including diarrhea and fatigue, with 25% of patients experiencing severe side effects, highlighting the need for ongoing studies to identify response and resistance markers.
Article Synopsis
- The study assesses the effectiveness of a dual checkpoint inhibition therapy (ipilimumab and nivolumab) on advanced non-epithelial ovarian cancers (NEOCs) in patients who have no other effective treatments available.
- In a clinical trial involving 17 patients, the therapy showed a 25% overall response rate in those with granulosa cell tumors, with some patients experiencing significant progression-free survival and overall survival benefits.
- However, the therapy had serious side effects, leading to treatment discontinuation in 18% of participants and no positive responses noted in carcinosarcoma cases.
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
Nathan D Seligson James L Chen Austin C Goodrich Brian A Van Tine Jordan D Campbell Howard Streicher
J Immunother Cancer
September 2024
Article Synopsis
- This phase II study (Alliance A091401) evaluates the effectiveness of nivolumab (N) alone and in combination with ipilimumab (N+I) on patients with different types of sarcomas, focusing on treatment responses and biomarkers.
- The study involved 66 patients with various sarcoma types, and while neither N nor N+I showed positive responses in gastrointestinal stromal tumors (GIST), N+I had a better response in dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS).
- Results highlighted that traditional biomarkers did not predict immunotherapy response, but genomic instability markers correlated with better clinical outcomes, emphasizing the need for more research in